kavita final cohort 2026 updated diabetes new
2026-01-05
excel: 25397
excel with dem: 20383
remove no baseline cre: 18319
remove missing esrd_kt!=0, eGFR_CRE_baseline <10 : 18157
remove missing last_cre_date< ICI_date:17937 (17752 with labs after ici date)
remove 216 placebo :17721
remove 3 death_date < ici_date(RPDR error): 17718
1year
| Characteristic | N = 1,2611 |
|---|---|
| age_ici | 70 (62, 76) |
| male | |
| 0 | 482 (38%) |
| 1 | 779 (62%) |
| Race | |
| Asian | 50 (4.0%) |
| Black | 80 (6.3%) |
| Other/Unknown | 68 (5.4%) |
| White | 1,063 (84%) |
| Ethnic_Group | |
| Hispanic | 45 (3.6%) |
| Non_hispanic | 1,144 (91%) |
| Other | 72 (5.7%) |
| ckd_incidence_1year | |
| 0 | 1,216 (96%) |
| 1 | 45 (3.6%) |
| ckd_progression_1year | |
| 0 | 1,199 (95%) |
| 1 | 62 (4.9%) |
| eskd_composite_1year | |
| 0 | 1,253 (99%) |
| 1 | 8 (0.6%) |
| ckd_composite_1year | |
| 0 | 1,195 (95%) |
| 1 | 66 (5.2%) |
| ckd_stage_1year | |
| 1 | 393 (31%) |
| 2 | 504 (40%) |
| 3 | 329 (26%) |
| 4 | 32 (2.5%) |
| 5 | 3 (0.2%) |
| ckd_stage_baseline | |
| 1 | 433 (34%) |
| 2 | 516 (41%) |
| 3 | 291 (23%) |
| 4 | 20 (1.6%) |
| 5 | 1 (<0.1%) |
| htn | |
| 0 | 139 (11%) |
| 1 | 1,122 (89%) |
| cad | |
| 0 | 731 (58%) |
| 1 | 530 (42%) |
| ace_arb | |
| 0 | 304 (24%) |
| 1 | 957 (76%) |
| diu | |
| 0 | 352 (28%) |
| 1 | 909 (72%) |
| ppi | |
| 0 | 239 (19%) |
| 1 | 1,022 (81%) |
| steroids | |
| 0 | 194 (15%) |
| 1 | 1,067 (85%) |
| smoking | |
| 0 | 482 (38%) |
| 1 | 779 (62%) |
| Bevacizumab | |
| 0 | 1,180 (94%) |
| 1 | 81 (6.4%) |
| Cisplatin | |
| 0 | 1,096 (87%) |
| 1 | 165 (13%) |
| Carboplatin | |
| 0 | 820 (65%) |
| 1 | 441 (35%) |
| Pemetrexed | |
| 0 | 1,082 (86%) |
| 1 | 179 (14%) |
| Gemcitabine | |
| 0 | 1,091 (87%) |
| 1 | 170 (13%) |
| Cetuximab | |
| 0 | 1,226 (97%) |
| 1 | 35 (2.8%) |
| Trastuzumab | |
| 0 | 1,229 (97%) |
| 1 | 32 (2.5%) |
| VEGF_TKI | |
| 0 | 1,097 (87%) |
| 1 | 164 (13%) |
| ICI_Class | |
| PD1 | 832 (66%) |
| Combination | 157 (12%) |
| CTLA4 | 44 (3.5%) |
| PDL1 | 228 (18%) |
| nephrotoxic_chemo | |
| 0 | 604 (48%) |
| 1 | 657 (52%) |
| pre_CRE_180days | 0.95 (0.75, 1.17) |
| pre_HGB_180days | 12.20 (10.90, 13.40) |
| Missing | 5 |
| pre_ALB_180days | 4.10 (3.80, 4.30) |
| Missing | 9 |
| eGFR_CRE_baseline | 79 (61, 95) |
| 1 Median (Q1, Q3); n (%) | |
2year
| Characteristic | N = 7631 |
|---|---|
| age_ici | 69 (61, 75) |
| male | |
| 0 | 295 (39%) |
| 1 | 468 (61%) |
| Race | |
| Asian | 25 (3.3%) |
| Black | 47 (6.2%) |
| Other/Unknown | 39 (5.1%) |
| White | 652 (85%) |
| Ethnic_Group | |
| Hispanic | 26 (3.4%) |
| Non_hispanic | 694 (91%) |
| Other | 43 (5.6%) |
| ckd_incidence_2year | |
| 0 | 711 (93%) |
| 1 | 52 (6.8%) |
| ckd_progression_2year | |
| 0 | 688 (90%) |
| 1 | 75 (9.8%) |
| eskd_composite_2year | |
| 0 | 752 (99%) |
| 1 | 11 (1.4%) |
| ckd_composite_2year | |
| 0 | 682 (89%) |
| 1 | 81 (11%) |
| ckd_stage_1year | |
| 1 | 235 (31%) |
| 2 | 309 (40%) |
| 3 | 199 (26%) |
| 4 | 18 (2.4%) |
| 5 | 2 (0.3%) |
| ckd_stage_2year | |
| 1 | 220 (29%) |
| 2 | 319 (42%) |
| 3 | 195 (26%) |
| 4 | 25 (3.3%) |
| 5 | 4 (0.5%) |
| ckd_stage_baseline | |
| 1 | 262 (34%) |
| 2 | 315 (41%) |
| 3 | 171 (22%) |
| 4 | 14 (1.8%) |
| 5 | 1 (0.1%) |
| htn | |
| 0 | 80 (10%) |
| 1 | 683 (90%) |
| cad | |
| 0 | 463 (61%) |
| 1 | 300 (39%) |
| ace_arb | |
| 0 | 181 (24%) |
| 1 | 582 (76%) |
| diu | |
| 0 | 213 (28%) |
| 1 | 550 (72%) |
| ppi | |
| 0 | 143 (19%) |
| 1 | 620 (81%) |
| steroids | |
| 0 | 118 (15%) |
| 1 | 645 (85%) |
| smoking | |
| 0 | 292 (38%) |
| 1 | 471 (62%) |
| Bevacizumab | |
| 0 | 718 (94%) |
| 1 | 45 (5.9%) |
| Cisplatin | |
| 0 | 669 (88%) |
| 1 | 94 (12%) |
| Carboplatin | |
| 0 | 508 (67%) |
| 1 | 255 (33%) |
| Pemetrexed | |
| 0 | 655 (86%) |
| 1 | 108 (14%) |
| Gemcitabine | |
| 0 | 673 (88%) |
| 1 | 90 (12%) |
| Cetuximab | |
| 0 | 743 (97%) |
| 1 | 20 (2.6%) |
| Trastuzumab | |
| 0 | 745 (98%) |
| 1 | 18 (2.4%) |
| VEGF_TKI | |
| 0 | 662 (87%) |
| 1 | 101 (13%) |
| ICI_Class | |
| PD1 | 510 (67%) |
| Combination | 90 (12%) |
| CTLA4 | 32 (4.2%) |
| PDL1 | 131 (17%) |
| nephrotoxic_chemo | |
| 0 | 387 (51%) |
| 1 | 376 (49%) |
| pre_CRE_180days | 0.95 (0.76, 1.17) |
| pre_HGB_180days | 12.40 (11.00, 13.60) |
| Missing | 4 |
| pre_ALB_180days | 4.10 (3.80, 4.30) |
| Missing | 5 |
| eGFR_CRE_baseline | 80 (61, 94) |
| 1 Median (Q1, Q3); n (%) | |
3year
| Characteristic | N = 4461 |
|---|---|
| age_ici | 68 (61, 75) |
| male | |
| 0 | 175 (39%) |
| 1 | 271 (61%) |
| Race | |
| Asian | 16 (3.6%) |
| Black | 24 (5.4%) |
| Other/Unknown | 24 (5.4%) |
| White | 382 (86%) |
| Ethnic_Group | |
| Hispanic | 15 (3.4%) |
| Non_hispanic | 406 (91%) |
| Other | 25 (5.6%) |
| ckd_incidence_3year | |
| 0 | 401 (90%) |
| 1 | 45 (10%) |
| ckd_progression_3year | |
| 0 | 382 (86%) |
| 1 | 64 (14%) |
| eskd_composite_3year | |
| 0 | 440 (99%) |
| 1 | 6 (1.3%) |
| ckd_composite_3year | |
| 0 | 379 (85%) |
| 1 | 67 (15%) |
| ckd_stage_1year | |
| 1 | 142 (32%) |
| 2 | 175 (39%) |
| 3 | 118 (26%) |
| 4 | 10 (2.2%) |
| 5 | 1 (0.2%) |
| ckd_stage_2year | |
| 1 | 134 (30%) |
| 2 | 187 (42%) |
| 3 | 114 (26%) |
| 4 | 11 (2.5%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 126 (28%) |
| 2 | 182 (41%) |
| 3 | 124 (28%) |
| 4 | 12 (2.7%) |
| 5 | 2 (0.4%) |
| ckd_stage_baseline | |
| 1 | 165 (37%) |
| 2 | 176 (39%) |
| 3 | 99 (22%) |
| 4 | 6 (1.3%) |
| 5 | 0 (0%) |
| htn | |
| 0 | 52 (12%) |
| 1 | 394 (88%) |
| cad | |
| 0 | 272 (61%) |
| 1 | 174 (39%) |
| ace_arb | |
| 0 | 98 (22%) |
| 1 | 348 (78%) |
| diu | |
| 0 | 129 (29%) |
| 1 | 317 (71%) |
| ppi | |
| 0 | 84 (19%) |
| 1 | 362 (81%) |
| steroids | |
| 0 | 69 (15%) |
| 1 | 377 (85%) |
| smoking | |
| 0 | 168 (38%) |
| 1 | 278 (62%) |
| Bevacizumab | |
| 0 | 424 (95%) |
| 1 | 22 (4.9%) |
| Cisplatin | |
| 0 | 392 (88%) |
| 1 | 54 (12%) |
| Carboplatin | |
| 0 | 305 (68%) |
| 1 | 141 (32%) |
| Pemetrexed | |
| 0 | 377 (85%) |
| 1 | 69 (15%) |
| Gemcitabine | |
| 0 | 394 (88%) |
| 1 | 52 (12%) |
| Cetuximab | |
| 0 | 434 (97%) |
| 1 | 12 (2.7%) |
| Trastuzumab | |
| 0 | 436 (98%) |
| 1 | 10 (2.2%) |
| VEGF_TKI | |
| 0 | 388 (87%) |
| 1 | 58 (13%) |
| ICI_Class | |
| PD1 | 304 (68%) |
| Combination | 51 (11%) |
| CTLA4 | 23 (5.2%) |
| PDL1 | 68 (15%) |
| nephrotoxic_chemo | |
| 0 | 246 (55%) |
| 1 | 200 (45%) |
| pre_CRE_180days | 0.94 (0.76, 1.17) |
| pre_HGB_180days | 12.60 (11.10, 13.70) |
| Missing | 3 |
| pre_ALB_180days | 4.10 (3.80, 4.30) |
| Missing | 3 |
| eGFR_CRE_baseline | 80 (62, 96) |
| 1 Median (Q1, Q3); n (%) | |
4year
| Characteristic | N = 2811 |
|---|---|
| age_ici | 68 (60, 74) |
| male | |
| 0 | 110 (39%) |
| 1 | 171 (61%) |
| Race | |
| Asian | 7 (2.5%) |
| Black | 11 (3.9%) |
| Other/Unknown | 17 (6.0%) |
| White | 246 (88%) |
| Ethnic_Group | |
| Hispanic | 11 (3.9%) |
| Non_hispanic | 251 (89%) |
| Other | 19 (6.8%) |
| ckd_incidence_4year | |
| 0 | 253 (90%) |
| 1 | 28 (10.0%) |
| ckd_progression_4year | |
| 0 | 235 (84%) |
| 1 | 46 (16%) |
| eskd_composite_4year | |
| 0 | 276 (98%) |
| 1 | 5 (1.8%) |
| ckd_composite_4year | |
| 0 | 233 (83%) |
| 1 | 48 (17%) |
| ckd_stage_1year | |
| 1 | 86 (31%) |
| 2 | 112 (40%) |
| 3 | 73 (26%) |
| 4 | 9 (3.2%) |
| 5 | 1 (0.4%) |
| ckd_stage_2year | |
| 1 | 81 (29%) |
| 2 | 120 (43%) |
| 3 | 71 (25%) |
| 4 | 9 (3.2%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 73 (26%) |
| 2 | 119 (42%) |
| 3 | 82 (29%) |
| 4 | 6 (2.1%) |
| 5 | 1 (0.4%) |
| ckd_stage_4year | |
| 1 | 78 (28%) |
| 2 | 115 (41%) |
| 3 | 82 (29%) |
| 4 | 5 (1.8%) |
| 5 | 1 (0.4%) |
| ckd_stage_baseline | |
| 1 | 96 (34%) |
| 2 | 116 (41%) |
| 3 | 65 (23%) |
| 4 | 4 (1.4%) |
| 5 | 0 (0%) |
| htn | |
| 0 | 32 (11%) |
| 1 | 249 (89%) |
| cad | |
| 0 | 167 (59%) |
| 1 | 114 (41%) |
| ace_arb | |
| 0 | 51 (18%) |
| 1 | 230 (82%) |
| diu | |
| 0 | 72 (26%) |
| 1 | 209 (74%) |
| ppi | |
| 0 | 56 (20%) |
| 1 | 225 (80%) |
| steroids | |
| 0 | 49 (17%) |
| 1 | 232 (83%) |
| smoking | |
| 0 | 105 (37%) |
| 1 | 176 (63%) |
| Bevacizumab | |
| 0 | 268 (95%) |
| 1 | 13 (4.6%) |
| Cisplatin | |
| 0 | 250 (89%) |
| 1 | 31 (11%) |
| Carboplatin | |
| 0 | 204 (73%) |
| 1 | 77 (27%) |
| Pemetrexed | |
| 0 | 239 (85%) |
| 1 | 42 (15%) |
| Gemcitabine | |
| 0 | 250 (89%) |
| 1 | 31 (11%) |
| Cetuximab | |
| 0 | 276 (98%) |
| 1 | 5 (1.8%) |
| Trastuzumab | |
| 0 | 274 (98%) |
| 1 | 7 (2.5%) |
| VEGF_TKI | |
| 0 | 244 (87%) |
| 1 | 37 (13%) |
| ICI_Class | |
| PD1 | 194 (69%) |
| Combination | 32 (11%) |
| CTLA4 | 12 (4.3%) |
| PDL1 | 43 (15%) |
| nephrotoxic_chemo | |
| 0 | 166 (59%) |
| 1 | 115 (41%) |
| pre_CRE_180days | 0.96 (0.78, 1.19) |
| pre_HGB_180days | 12.60 (11.10, 13.90) |
| Missing | 1 |
| pre_ALB_180days | 4.10 (3.80, 4.40) |
| Missing | 1 |
| eGFR_CRE_baseline | 79 (61, 95) |
| 1 Median (Q1, Q3); n (%) | |
5year
| Characteristic | N = 1771 |
|---|---|
| age_ici | 67 (59, 74) |
| male | |
| 0 | 70 (40%) |
| 1 | 107 (60%) |
| Race | |
| Asian | 3 (1.7%) |
| Black | 10 (5.6%) |
| Other/Unknown | 13 (7.3%) |
| White | 151 (85%) |
| Ethnic_Group | |
| Hispanic | 8 (4.5%) |
| Non_hispanic | 155 (88%) |
| Other | 14 (7.9%) |
| ckd_incidence_5year | |
| 0 | 158 (89%) |
| 1 | 19 (11%) |
| ckd_progression_5year | |
| 0 | 141 (80%) |
| 1 | 36 (20%) |
| eskd_composite_5year | |
| 0 | 174 (98%) |
| 1 | 3 (1.7%) |
| ckd_composite_5year | |
| 0 | 139 (79%) |
| 1 | 38 (21%) |
| ckd_stage_1year | |
| 1 | 53 (30%) |
| 2 | 75 (42%) |
| 3 | 45 (25%) |
| 4 | 4 (2.3%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 50 (28%) |
| 2 | 81 (46%) |
| 3 | 42 (24%) |
| 4 | 4 (2.3%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 46 (26%) |
| 2 | 84 (47%) |
| 3 | 45 (25%) |
| 4 | 1 (0.6%) |
| 5 | 1 (0.6%) |
| ckd_stage_4year | |
| 1 | 50 (28%) |
| 2 | 78 (44%) |
| 3 | 47 (27%) |
| 4 | 1 (0.6%) |
| 5 | 1 (0.6%) |
| ckd_stage_5year | |
| 1 | 44 (25%) |
| 2 | 87 (49%) |
| 3 | 40 (23%) |
| 4 | 5 (2.8%) |
| 5 | 1 (0.6%) |
| ckd_stage_baseline | |
| 1 | 60 (34%) |
| 2 | 76 (43%) |
| 3 | 38 (21%) |
| 4 | 3 (1.7%) |
| 5 | 0 (0%) |
| htn | |
| 0 | 20 (11%) |
| 1 | 157 (89%) |
| cad | |
| 0 | 109 (62%) |
| 1 | 68 (38%) |
| ace_arb | |
| 0 | 35 (20%) |
| 1 | 142 (80%) |
| diu | |
| 0 | 43 (24%) |
| 1 | 134 (76%) |
| ppi | |
| 0 | 35 (20%) |
| 1 | 142 (80%) |
| steroids | |
| 0 | 34 (19%) |
| 1 | 143 (81%) |
| smoking | |
| 0 | 68 (38%) |
| 1 | 109 (62%) |
| Bevacizumab | |
| 0 | 169 (95%) |
| 1 | 8 (4.5%) |
| Cisplatin | |
| 0 | 160 (90%) |
| 1 | 17 (9.6%) |
| Carboplatin | |
| 0 | 127 (72%) |
| 1 | 50 (28%) |
| Pemetrexed | |
| 0 | 155 (88%) |
| 1 | 22 (12%) |
| Gemcitabine | |
| 0 | 158 (89%) |
| 1 | 19 (11%) |
| Cetuximab | |
| 0 | 175 (99%) |
| 1 | 2 (1.1%) |
| Trastuzumab | |
| 0 | 175 (99%) |
| 1 | 2 (1.1%) |
| VEGF_TKI | |
| 0 | 159 (90%) |
| 1 | 18 (10%) |
| ICI_Class | |
| PD1 | 124 (70%) |
| Combination | 14 (7.9%) |
| CTLA4 | 9 (5.1%) |
| PDL1 | 30 (17%) |
| nephrotoxic_chemo | |
| 0 | 108 (61%) |
| 1 | 69 (39%) |
| pre_CRE_180days | 0.95 (0.75, 1.16) |
| pre_HGB_180days | 12.60 (11.15, 13.85) |
| Missing | 1 |
| pre_ALB_180days | 4.10 (3.80, 4.30) |
| Missing | 1 |
| eGFR_CRE_baseline | 79 (61, 96) |
| 1 Median (Q1, Q3); n (%) | |
6year
| Characteristic | N = 1141 |
|---|---|
| age_ici | 65 (59, 74) |
| male | |
| 0 | 47 (41%) |
| 1 | 67 (59%) |
| Race | |
| Asian | 2 (1.8%) |
| Black | 9 (7.9%) |
| Other/Unknown | 10 (8.8%) |
| White | 93 (82%) |
| Ethnic_Group | |
| Hispanic | 5 (4.4%) |
| Non_hispanic | 98 (86%) |
| Other | 11 (9.6%) |
| ckd_incidence_6year | |
| 0 | 97 (85%) |
| 1 | 17 (15%) |
| ckd_progression_6year | |
| 0 | 86 (75%) |
| 1 | 28 (25%) |
| eskd_composite_6year | |
| 0 | 112 (98%) |
| 1 | 2 (1.8%) |
| ckd_composite_6year | 30 (26%) |
| ckd_stage_1year | |
| 1 | 38 (33%) |
| 2 | 49 (43%) |
| 3 | 26 (23%) |
| 4 | 1 (0.9%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 35 (31%) |
| 2 | 53 (46%) |
| 3 | 26 (23%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 35 (31%) |
| 2 | 50 (44%) |
| 3 | 28 (25%) |
| 4 | 1 (0.9%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 36 (32%) |
| 2 | 49 (43%) |
| 3 | 29 (25%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 31 (27%) |
| 2 | 56 (49%) |
| 3 | 25 (22%) |
| 4 | 2 (1.8%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 30 (26%) |
| 2 | 56 (49%) |
| 3 | 22 (19%) |
| 4 | 6 (5.3%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 43 (38%) |
| 2 | 46 (40%) |
| 3 | 24 (21%) |
| 4 | 1 (0.9%) |
| 5 | 0 (0%) |
| htn | |
| 0 | 14 (12%) |
| 1 | 100 (88%) |
| cad | |
| 0 | 75 (66%) |
| 1 | 39 (34%) |
| ace_arb | |
| 0 | 24 (21%) |
| 1 | 90 (79%) |
| diu | |
| 0 | 30 (26%) |
| 1 | 84 (74%) |
| ppi | |
| 0 | 23 (20%) |
| 1 | 91 (80%) |
| steroids | |
| 0 | 22 (19%) |
| 1 | 92 (81%) |
| smoking | |
| 0 | 48 (42%) |
| 1 | 66 (58%) |
| Bevacizumab | |
| 0 | 110 (96%) |
| 1 | 4 (3.5%) |
| Cisplatin | |
| 0 | 102 (89%) |
| 1 | 12 (11%) |
| Carboplatin | |
| 0 | 83 (73%) |
| 1 | 31 (27%) |
| Pemetrexed | |
| 0 | 99 (87%) |
| 1 | 15 (13%) |
| Gemcitabine | |
| 0 | 104 (91%) |
| 1 | 10 (8.8%) |
| Cetuximab | |
| 0 | 113 (99%) |
| 1 | 1 (0.9%) |
| Trastuzumab | |
| 0 | 113 (99%) |
| 1 | 1 (0.9%) |
| VEGF_TKI | |
| 0 | 105 (92%) |
| 1 | 9 (7.9%) |
| ICI_Class | |
| PD1 | 75 (66%) |
| Combination | 8 (7.0%) |
| CTLA4 | 8 (7.0%) |
| PDL1 | 23 (20%) |
| nephrotoxic_chemo | |
| 0 | 73 (64%) |
| 1 | 41 (36%) |
| pre_CRE_180days | 0.93 (0.72, 1.12) |
| pre_HGB_180days | 12.60 (11.10, 13.90) |
| pre_ALB_180days | 4.10 (3.80, 4.30) |
| eGFR_CRE_baseline | 82 (66, 98) |
| 1 Median (Q1, Q3); n (%) | |
7year
| Characteristic | N = 761 |
|---|---|
| age_ici | 64 (58, 73) |
| male | |
| 0 | 28 (37%) |
| 1 | 48 (63%) |
| Race | |
| Asian | 1 (1.3%) |
| Black | 6 (7.9%) |
| Other/Unknown | 7 (9.2%) |
| White | 62 (82%) |
| Ethnic_Group | |
| Hispanic | 4 (5.3%) |
| Non_hispanic | 64 (84%) |
| Other | 8 (11%) |
| ckd_incidence_7year | |
| 0 | 60 (79%) |
| 1 | 16 (21%) |
| ckd_progression_7year | |
| 0 | 56 (74%) |
| 1 | 20 (26%) |
| eskd_composite_7year | |
| 0 | 75 (99%) |
| 1 | 1 (1.3%) |
| ckd_composite_7year | 21 (28%) |
| ckd_stage_1year | |
| 1 | 28 (37%) |
| 2 | 32 (42%) |
| 3 | 15 (20%) |
| 4 | 1 (1.3%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 25 (33%) |
| 2 | 34 (45%) |
| 3 | 17 (22%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 24 (32%) |
| 2 | 35 (46%) |
| 3 | 17 (22%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 25 (33%) |
| 2 | 31 (41%) |
| 3 | 20 (26%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 20 (26%) |
| 2 | 39 (51%) |
| 3 | 16 (21%) |
| 4 | 1 (1.3%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 20 (26%) |
| 2 | 37 (49%) |
| 3 | 15 (20%) |
| 4 | 4 (5.3%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 20 (26%) |
| 2 | 33 (43%) |
| 3 | 19 (25%) |
| 4 | 3 (3.9%) |
| 5 | 1 (1.3%) |
| ckd_stage_baseline | |
| 1 | 30 (39%) |
| 2 | 30 (39%) |
| 3 | 15 (20%) |
| 4 | 1 (1.3%) |
| 5 | 0 (0%) |
| htn | |
| 0 | 10 (13%) |
| 1 | 66 (87%) |
| cad | |
| 0 | 53 (70%) |
| 1 | 23 (30%) |
| ace_arb | |
| 0 | 15 (20%) |
| 1 | 61 (80%) |
| diu | |
| 0 | 24 (32%) |
| 1 | 52 (68%) |
| ppi | |
| 0 | 15 (20%) |
| 1 | 61 (80%) |
| steroids | |
| 0 | 14 (18%) |
| 1 | 62 (82%) |
| smoking | |
| 0 | 29 (38%) |
| 1 | 47 (62%) |
| Bevacizumab | |
| 0 | 72 (95%) |
| 1 | 4 (5.3%) |
| Cisplatin | |
| 0 | 70 (92%) |
| 1 | 6 (7.9%) |
| Carboplatin | |
| 0 | 56 (74%) |
| 1 | 20 (26%) |
| Pemetrexed | |
| 0 | 66 (87%) |
| 1 | 10 (13%) |
| Gemcitabine | |
| 0 | 69 (91%) |
| 1 | 7 (9.2%) |
| Cetuximab | |
| 0 | 76 (100%) |
| 1 | 0 (0%) |
| Trastuzumab | |
| 0 | 75 (99%) |
| 1 | 1 (1.3%) |
| VEGF_TKI | |
| 0 | 70 (92%) |
| 1 | 6 (7.9%) |
| ICI_Class | |
| PD1 | 53 (70%) |
| Combination | 4 (5.3%) |
| CTLA4 | 6 (7.9%) |
| PDL1 | 13 (17%) |
| nephrotoxic_chemo | |
| 0 | 50 (66%) |
| 1 | 26 (34%) |
| pre_CRE_180days | 0.95 (0.76, 1.11) |
| pre_HGB_180days | 12.60 (11.00, 13.90) |
| pre_ALB_180days | 4.10 (3.90, 4.30) |
| eGFR_CRE_baseline | 82 (69, 98) |
| 1 Median (Q1, Q3); n (%) | |
8year
| Characteristic | N = 401 |
|---|---|
| age_ici | 67 (58, 73) |
| male | |
| 0 | 12 (30%) |
| 1 | 28 (70%) |
| Race | |
| Asian | 0 (0%) |
| Black | 3 (7.5%) |
| Other/Unknown | 2 (5.0%) |
| White | 35 (88%) |
| Ethnic_Group | |
| Hispanic | 1 (2.5%) |
| Non_hispanic | 34 (85%) |
| Other | 5 (13%) |
| ckd_incidence_8year | |
| 0 | 26 (65%) |
| 1 | 14 (35%) |
| ckd_progression_8year | |
| 0 | 22 (55%) |
| 1 | 18 (45%) |
| eskd_composite_8year | |
| 0 | 40 (100%) |
| 1 | 0 (0%) |
| ckd_composite_8year | 18 (45%) |
| ckd_stage_1year | |
| 1 | 13 (33%) |
| 2 | 18 (45%) |
| 3 | 9 (23%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 9 (23%) |
| 2 | 21 (53%) |
| 3 | 10 (25%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 11 (28%) |
| 2 | 19 (48%) |
| 3 | 10 (25%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 13 (33%) |
| 2 | 14 (35%) |
| 3 | 13 (33%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 9 (23%) |
| 2 | 19 (48%) |
| 3 | 12 (30%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 8 (20%) |
| 2 | 20 (50%) |
| 3 | 11 (28%) |
| 4 | 1 (2.5%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 9 (23%) |
| 2 | 14 (35%) |
| 3 | 15 (38%) |
| 4 | 2 (5.0%) |
| 5 | 0 (0%) |
| ckd_stage_8year | |
| 1 | 8 (20%) |
| 2 | 14 (35%) |
| 3 | 16 (40%) |
| 4 | 2 (5.0%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 12 (30%) |
| 2 | 17 (43%) |
| 3 | 11 (28%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| htn | |
| 0 | 2 (5.0%) |
| 1 | 38 (95%) |
| cad | |
| 0 | 26 (65%) |
| 1 | 14 (35%) |
| ace_arb | |
| 0 | 8 (20%) |
| 1 | 32 (80%) |
| diu | |
| 0 | 11 (28%) |
| 1 | 29 (73%) |
| ppi | |
| 0 | 9 (23%) |
| 1 | 31 (78%) |
| steroids | |
| 0 | 10 (25%) |
| 1 | 30 (75%) |
| smoking | |
| 0 | 15 (38%) |
| 1 | 25 (63%) |
| Bevacizumab | |
| 0 | 38 (95%) |
| 1 | 2 (5.0%) |
| Cisplatin | |
| 0 | 38 (95%) |
| 1 | 2 (5.0%) |
| Carboplatin | |
| 0 | 32 (80%) |
| 1 | 8 (20%) |
| Pemetrexed | |
| 0 | 36 (90%) |
| 1 | 4 (10%) |
| Gemcitabine | |
| 0 | 37 (93%) |
| 1 | 3 (7.5%) |
| Cetuximab | |
| 0 | 40 (100%) |
| 1 | 0 (0%) |
| Trastuzumab | |
| 0 | 39 (98%) |
| 1 | 1 (2.5%) |
| VEGF_TKI | |
| 0 | 38 (95%) |
| 1 | 2 (5.0%) |
| ICI_Class | |
| PD1 | 26 (65%) |
| Combination | 2 (5.0%) |
| CTLA4 | 5 (13%) |
| PDL1 | 7 (18%) |
| nephrotoxic_chemo | |
| 0 | 30 (75%) |
| 1 | 10 (25%) |
| pre_CRE_180days | 1.02 (0.78, 1.24) |
| pre_HGB_180days | 12.55 (10.95, 13.95) |
| pre_ALB_180days | 4.10 (3.90, 4.30) |
| eGFR_CRE_baseline | 79 (59, 95) |
| 1 Median (Q1, Q3); n (%) | |
9year
| Characteristic | N = 171 |
|---|---|
| age_ici | 67 (57, 74) |
| male | |
| 0 | 6 (35%) |
| 1 | 11 (65%) |
| Race | |
| Asian | 0 (0%) |
| Black | 0 (0%) |
| Other/Unknown | 0 (0%) |
| White | 17 (100%) |
| Ethnic_Group | |
| Hispanic | 0 (0%) |
| Non_hispanic | 16 (94%) |
| Other | 1 (5.9%) |
| ckd_incidence_9year | |
| 0 | 12 (71%) |
| 1 | 5 (29%) |
| ckd_progression_9year | |
| 0 | 10 (59%) |
| 1 | 7 (41%) |
| eskd_composite_9year | |
| 0 | 17 (100%) |
| 1 | 0 (0%) |
| ckd_composite_9year | 7 (41%) |
| ckd_stage_1year | |
| 1 | 4 (24%) |
| 2 | 10 (59%) |
| 3 | 3 (18%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 3 (18%) |
| 2 | 10 (59%) |
| 3 | 4 (24%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 4 (24%) |
| 2 | 9 (53%) |
| 3 | 4 (24%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 7 (41%) |
| 2 | 5 (29%) |
| 3 | 5 (29%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 4 (24%) |
| 2 | 8 (47%) |
| 3 | 5 (29%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 4 (24%) |
| 2 | 7 (41%) |
| 3 | 6 (35%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 6 (35%) |
| 2 | 5 (29%) |
| 3 | 6 (35%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_8year | |
| 1 | 5 (29%) |
| 2 | 6 (35%) |
| 3 | 5 (29%) |
| 4 | 1 (5.9%) |
| 5 | 0 (0%) |
| ckd_stage_9year | |
| 1 | 7 (41%) |
| 2 | 3 (18%) |
| 3 | 7 (41%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 4 (24%) |
| 2 | 9 (53%) |
| 3 | 4 (24%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| htn | |
| 0 | 0 (0%) |
| 1 | 17 (100%) |
| cad | |
| 0 | 12 (71%) |
| 1 | 5 (29%) |
| ace_arb | |
| 0 | 4 (24%) |
| 1 | 13 (76%) |
| diu | |
| 0 | 4 (24%) |
| 1 | 13 (76%) |
| ppi | |
| 0 | 2 (12%) |
| 1 | 15 (88%) |
| steroids | |
| 0 | 3 (18%) |
| 1 | 14 (82%) |
| smoking | |
| 0 | 5 (29%) |
| 1 | 12 (71%) |
| Bevacizumab | |
| 0 | 16 (94%) |
| 1 | 1 (5.9%) |
| Cisplatin | |
| 0 | 16 (94%) |
| 1 | 1 (5.9%) |
| Carboplatin | |
| 0 | 12 (71%) |
| 1 | 5 (29%) |
| Pemetrexed | |
| 0 | 14 (82%) |
| 1 | 3 (18%) |
| Gemcitabine | |
| 0 | 17 (100%) |
| 1 | 0 (0%) |
| Cetuximab | |
| 0 | 17 (100%) |
| 1 | 0 (0%) |
| Trastuzumab | |
| 0 | 16 (94%) |
| 1 | 1 (5.9%) |
| VEGF_TKI | |
| 0 | 16 (94%) |
| 1 | 1 (5.9%) |
| ICI_Class | |
| PD1 | 9 (53%) |
| Combination | 0 (0%) |
| CTLA4 | 4 (24%) |
| PDL1 | 4 (24%) |
| nephrotoxic_chemo | |
| 0 | 11 (65%) |
| 1 | 6 (35%) |
| pre_CRE_180days | 1.02 (0.83, 1.09) |
| pre_HGB_180days | 12.60 (11.70, 14.40) |
| pre_ALB_180days | |
| 3.5 | 1 (5.9%) |
| 3.9 | 1 (5.9%) |
| 4 | 2 (12%) |
| 4.1 | 2 (12%) |
| 4.2 | 5 (29%) |
| 4.3 | 3 (18%) |
| 4.4 | 2 (12%) |
| 4.8 | 1 (5.9%) |
| eGFR_CRE_baseline | 77 (61, 88) |
| 1 Median (Q1, Q3); n (%) | |
10year
| Characteristic | N = 61 |
|---|---|
| age_ici | |
| 60 | 1 (17%) |
| 67 | 1 (17%) |
| 71 | 1 (17%) |
| 72 | 1 (17%) |
| 74 | 1 (17%) |
| 75 | 1 (17%) |
| male | |
| 0 | 2 (33%) |
| 1 | 4 (67%) |
| Race | |
| Asian | 0 (0%) |
| Black | 0 (0%) |
| Other/Unknown | 0 (0%) |
| White | 6 (100%) |
| Ethnic_Group | |
| Hispanic | 0 (0%) |
| Non_hispanic | 6 (100%) |
| Other | 0 (0%) |
| ckd_incidence_10year | |
| 0 | 3 (50%) |
| 1 | 3 (50%) |
| ckd_progression_10year | |
| 0 | 2 (33%) |
| 1 | 4 (67%) |
| eskd_composite_10year | |
| 0 | 5 (83%) |
| 1 | 1 (17%) |
| ckd_composite_10year | 4 (67%) |
| ckd_stage_1year | |
| 1 | 1 (17%) |
| 2 | 3 (50%) |
| 3 | 2 (33%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 1 (17%) |
| 2 | 2 (33%) |
| 3 | 3 (50%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 1 (17%) |
| 2 | 2 (33%) |
| 3 | 3 (50%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 1 (17%) |
| 2 | 2 (33%) |
| 3 | 3 (50%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 1 (17%) |
| 2 | 2 (33%) |
| 3 | 3 (50%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 1 (17%) |
| 2 | 2 (33%) |
| 3 | 3 (50%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 0 (0%) |
| 2 | 2 (33%) |
| 3 | 4 (67%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_8year | |
| 1 | 1 (17%) |
| 2 | 1 (17%) |
| 3 | 3 (50%) |
| 4 | 1 (17%) |
| 5 | 0 (0%) |
| ckd_stage_9year | |
| 1 | 1 (17%) |
| 2 | 0 (0%) |
| 3 | 5 (83%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_10year | |
| 1 | 0 (0%) |
| 2 | 1 (17%) |
| 3 | 3 (50%) |
| 4 | 2 (33%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 1 (17%) |
| 2 | 3 (50%) |
| 3 | 2 (33%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| htn | |
| 0 | 0 (0%) |
| 1 | 6 (100%) |
| cad | |
| 0 | 4 (67%) |
| 1 | 2 (33%) |
| ace_arb | |
| 0 | 0 (0%) |
| 1 | 6 (100%) |
| diu | |
| 0 | 1 (17%) |
| 1 | 5 (83%) |
| ppi | |
| 0 | 0 (0%) |
| 1 | 6 (100%) |
| steroids | |
| 0 | 1 (17%) |
| 1 | 5 (83%) |
| smoking | |
| 0 | 0 (0%) |
| 1 | 6 (100%) |
| Bevacizumab | |
| 0 | 6 (100%) |
| 1 | 0 (0%) |
| Cisplatin | |
| 0 | 5 (83%) |
| 1 | 1 (17%) |
| Carboplatin | |
| 0 | 5 (83%) |
| 1 | 1 (17%) |
| Pemetrexed | |
| 0 | 5 (83%) |
| 1 | 1 (17%) |
| Gemcitabine | |
| 0 | 6 (100%) |
| 1 | 0 (0%) |
| Cetuximab | |
| 0 | 6 (100%) |
| 1 | 0 (0%) |
| Trastuzumab | |
| 0 | 5 (83%) |
| 1 | 1 (17%) |
| VEGF_TKI | |
| 0 | 6 (100%) |
| 1 | 0 (0%) |
| ICI_Class | |
| PD1 | 3 (50%) |
| Combination | 0 (0%) |
| CTLA4 | 3 (50%) |
| PDL1 | 0 (0%) |
| nephrotoxic_chemo | |
| 0 | 4 (67%) |
| 1 | 2 (33%) |
| pre_CRE_180days | |
| 0.66 | 1 (17%) |
| 0.81 | 1 (17%) |
| 1.01 | 1 (17%) |
| 1.02 | 1 (17%) |
| 1.3 | 1 (17%) |
| 1.52 | 1 (17%) |
| pre_HGB_180days | |
| 11.3 | 1 (17%) |
| 12.2 | 1 (17%) |
| 13.3 | 1 (17%) |
| 13.9 | 1 (17%) |
| 14.6 | 1 (17%) |
| 14.8 | 1 (17%) |
| pre_ALB_180days | |
| 4.1 | 1 (17%) |
| 4.2 | 1 (17%) |
| 4.3 | 2 (33%) |
| 4.4 | 1 (17%) |
| 4.8 | 1 (17%) |
| eGFR_CRE_baseline | |
| 47.0718538399253 | 1 (17%) |
| 59.186554146736 | 1 (17%) |
| 61.3166133202947 | 1 (17%) |
| 80.4651484382125 | 1 (17%) |
| 82.827699890859 | 1 (17%) |
| 104.256040676399 | 1 (17%) |
| 1 n (%) | |
CIF
CIF survival >365 days Event number : death + ckd composite
ckd_stage vs ckd_composite_1year
| 0 (N=1195) |
1 (N=66) |
Overall (N=1261) |
|
|---|---|---|---|
| ckd_stage_baseline | |||
| 1 | 424 (35.5%) | 9 (13.6%) | 433 (34.3%) |
| 2 | 479 (40.1%) | 37 (56.1%) | 516 (40.9%) |
| 3 | 274 (22.9%) | 17 (25.8%) | 291 (23.1%) |
| 4 | 18 (1.5%) | 2 (3.0%) | 20 (1.6%) |
| 5 | 0 (0%) | 1 (1.5%) | 1 (0.1%) |
| factor(ckd_stage_1year) | |||
| 1 | 393 (32.9%) | 0 (0%) | 393 (31.2%) |
| 2 | 498 (41.7%) | 6 (9.1%) | 504 (40.0%) |
| 3 | 283 (23.7%) | 46 (69.7%) | 329 (26.1%) |
| 4 | 21 (1.8%) | 11 (16.7%) | 32 (2.5%) |
| 5 | 0 (0%) | 3 (4.5%) | 3 (0.2%) |
ckd_stage vs ckd_composite_2year
| 0 (N=682) |
1 (N=81) |
Overall (N=763) |
|
|---|---|---|---|
| ckd_stage_baseline | |||
| 1 | 249 (36.5%) | 13 (16.0%) | 262 (34.3%) |
| 2 | 273 (40.0%) | 42 (51.9%) | 315 (41.3%) |
| 3 | 149 (21.8%) | 22 (27.2%) | 171 (22.4%) |
| 4 | 11 (1.6%) | 3 (3.7%) | 14 (1.8%) |
| 5 | 0 (0%) | 1 (1.2%) | 1 (0.1%) |
| factor(ckd_stage_2year) | |||
| 1 | 220 (32.3%) | 0 (0%) | 220 (28.8%) |
| 2 | 309 (45.3%) | 10 (12.3%) | 319 (41.8%) |
| 3 | 137 (20.1%) | 58 (71.6%) | 195 (25.6%) |
| 4 | 16 (2.3%) | 9 (11.1%) | 25 (3.3%) |
| 5 | 0 (0%) | 4 (4.9%) | 4 (0.5%) |
ckd_stage vs ckd_composite_3year
| 0 (N=379) |
1 (N=67) |
Overall (N=446) |
|
|---|---|---|---|
| ckd_stage_baseline | |||
| 1 | 151 (39.8%) | 14 (20.9%) | 165 (37.0%) |
| 2 | 144 (38.0%) | 32 (47.8%) | 176 (39.5%) |
| 3 | 80 (21.1%) | 19 (28.4%) | 99 (22.2%) |
| 4 | 4 (1.1%) | 2 (3.0%) | 6 (1.3%) |
| 5 | 0 (0%) | 0 (0%) | 0 (0%) |
| factor(ckd_stage_3year) | |||
| 1 | 125 (33.0%) | 1 (1.5%) | 126 (28.3%) |
| 2 | 168 (44.3%) | 14 (20.9%) | 182 (40.8%) |
| 3 | 81 (21.4%) | 43 (64.2%) | 124 (27.8%) |
| 4 | 5 (1.3%) | 7 (10.4%) | 12 (2.7%) |
| 5 | 0 (0%) | 2 (3.0%) | 2 (0.4%) |
ckd_stage vs ckd_composite_4year
| 0 (N=233) |
1 (N=48) |
Overall (N=281) |
|
|---|---|---|---|
| ckd_stage_baseline | |||
| 1 | 85 (36.5%) | 11 (22.9%) | 96 (34.2%) |
| 2 | 98 (42.1%) | 18 (37.5%) | 116 (41.3%) |
| 3 | 47 (20.2%) | 18 (37.5%) | 65 (23.1%) |
| 4 | 3 (1.3%) | 1 (2.1%) | 4 (1.4%) |
| 5 | 0 (0%) | 0 (0%) | 0 (0%) |
| factor(ckd_stage_4year) | |||
| 1 | 77 (33.0%) | 1 (2.1%) | 78 (27.8%) |
| 2 | 105 (45.1%) | 10 (20.8%) | 115 (40.9%) |
| 3 | 49 (21.0%) | 33 (68.8%) | 82 (29.2%) |
| 4 | 2 (0.9%) | 3 (6.3%) | 5 (1.8%) |
| 5 | 0 (0%) | 1 (2.1%) | 1 (0.4%) |
ckd_stage vs ckd_composite_5year
| 0 (N=139) |
1 (N=38) |
Overall (N=177) |
|
|---|---|---|---|
| ckd_stage_baseline | |||
| 1 | 57 (41.0%) | 3 (7.9%) | 60 (33.9%) |
| 2 | 59 (42.4%) | 17 (44.7%) | 76 (42.9%) |
| 3 | 21 (15.1%) | 17 (44.7%) | 38 (21.5%) |
| 4 | 2 (1.4%) | 1 (2.6%) | 3 (1.7%) |
| 5 | 0 (0%) | 0 (0%) | 0 (0%) |
| factor(ckd_stage_5year) | |||
| 1 | 42 (30.2%) | 2 (5.3%) | 44 (24.9%) |
| 2 | 79 (56.8%) | 8 (21.1%) | 87 (49.2%) |
| 3 | 15 (10.8%) | 25 (65.8%) | 40 (22.6%) |
| 4 | 3 (2.2%) | 2 (5.3%) | 5 (2.8%) |
| 5 | 0 (0%) | 1 (2.6%) | 1 (0.6%) |
landmark 1year
landmark 2year
landmark 3year
landmark 4year
landmark 5year
cox model outcome: death. Survival 5 year
| Characteristic | N | HR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| year_10 | 177 | 1.02 | 0.87, 1.19 | 0.799 |
| male | 177 | |||
| 0 | — | — | ||
| 1 | 0.87 | 0.62, 1.21 | 0.398 | |
| Race | 177 | |||
| Asian | — | — | ||
| Black | 0.62 | 0.13, 2.98 | 0.548 | |
| Other/Unknown | 0.75 | 0.16, 3.38 | 0.704 | |
| White | 0.83 | 0.20, 3.37 | 0.793 | |
| dm | 177 | |||
| htn | 177 | |||
| 0 | — | — | ||
| 1 | 0.61 | 0.38, 0.98 | 0.043 | |
| cad | 177 | |||
| 0 | — | — | ||
| 1 | 1.13 | 0.81, 1.58 | 0.474 | |
| ace_arb | 177 | |||
| 0 | — | — | ||
| 1 | 0.89 | 0.60, 1.32 | 0.558 | |
| diu | 177 | |||
| 0 | — | — | ||
| 1 | 0.88 | 0.62, 1.26 | 0.498 | |
| ppi | 177 | |||
| 0 | — | — | ||
| 1 | 0.95 | 0.64, 1.41 | 0.784 | |
| steroids | 177 | |||
| 0 | — | — | ||
| 1 | 1.06 | 0.71, 1.60 | 0.769 | |
| smoking | 177 | |||
| 0 | — | — | ||
| 1 | 0.90 | 0.64, 1.26 | 0.533 | |
| ckd_stage_baseline | 177 | |||
| 1 | — | — | ||
| 2 | 1.03 | 0.71, 1.50 | 0.863 | |
| 3 | 0.80 | 0.51, 1.27 | 0.346 | |
| 4 | 2.64 | 0.82, 8.50 | 0.105 | |
| 5 | ||||
| ckd_stage_5year | 177 | |||
| 1 | — | — | ||
| 2 | 1.04 | 0.70, 1.54 | 0.859 | |
| 3 | 0.77 | 0.47, 1.25 | 0.290 | |
| 4 | 2.70 | 1.05, 6.93 | 0.039 | |
| 5 | 0.00 | 0.00, Inf | 0.996 | |
| Bevacizumab | 177 | |||
| 0 | — | — | ||
| 1 | 1.15 | 0.54, 2.47 | 0.717 | |
| Cisplatin | 177 | |||
| 0 | — | — | ||
| 1 | 1.09 | 0.62, 1.94 | 0.760 | |
| Carboplatin | 177 | |||
| 0 | — | — | ||
| 1 | 1.00 | 0.69, 1.46 | 0.995 | |
| Pemetrexed | 177 | |||
| 0 | — | — | ||
| 1 | 0.92 | 0.56, 1.54 | 0.761 | |
| Gemcitabine | 177 | |||
| 0 | — | — | ||
| 1 | 1.37 | 0.78, 2.38 | 0.272 | |
| Cetuximab | 177 | |||
| 0 | — | — | ||
| 1 | 0.00 | 0.00, Inf | 0.994 | |
| Trastuzumab | 177 | |||
| 0 | — | — | ||
| 1 | 0.30 | 0.04, 2.15 | 0.229 | |
| VEGF_TKI | 177 | |||
| 0 | — | — | ||
| 1 | 1.36 | 0.78, 2.37 | 0.275 | |
| ICI_Class | 177 | |||
| PD1 | — | — | ||
| Combination | 1.57 | 0.88, 2.80 | 0.130 | |
| CTLA4 | 0.21 | 0.09, 0.54 | 0.001 | |
| PDL1 | 0.88 | 0.56, 1.37 | 0.573 | |
| cancer_type | 177 | |||
| breast | — | — | ||
| cutaneous / melanoma | 0.34 | 0.10, 1.14 | 0.080 | |
| gi | 0.99 | 0.25, 3.98 | 0.992 | |
| gu | 0.67 | 0.20, 2.23 | 0.517 | |
| gyn | 0.88 | 0.21, 3.70 | 0.862 | |
| head and neck | 0.57 | 0.15, 2.11 | 0.395 | |
| heme | 0.56 | 0.15, 2.00 | 0.367 | |
| neuro | 0.56 | 0.09, 3.39 | 0.526 | |
| sarcoma | 0.76 | 0.13, 4.58 | 0.762 | |
| thoracic | 0.49 | 0.15, 1.62 | 0.244 | |
| eGFR_CRE_baseline_decrease_10 | 177 | 1.00 | 0.92, 1.08 | 0.910 |
| pre_CRE_180days | 177 | 0.92 | 0.57, 1.49 | 0.736 |
| ckd_composite_5year | 177 | |||
| 0 | — | — | ||
| 1 | 0.82 | 0.54, 1.26 | 0.373 | |
| 1 HR = Hazard Ratio, CI = Confidence Interval | ||||
logistic regression outcome: ckd_composite_5year
| Characteristic | N | OR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| year_10 | 177 | 1.78 | 1.21, 2.73 | 0.005 |
| male | 177 | |||
| 0 | — | — | ||
| 1 | 0.58 | 0.28, 1.20 | 0.139 | |
| htn | 177 | |||
| 0 | — | — | ||
| 1 | 1.63 | 0.51, 7.25 | 0.458 | |
| cad | 177 | |||
| 0 | — | — | ||
| 1 | 3.70 | 1.77, 8.00 | <0.001 | |
| ace_arb | 177 | |||
| 0 | — | — | ||
| 1 | 1.82 | 0.70, 5.66 | 0.253 | |
| diu | 177 | |||
| 0 | — | — | ||
| 1 | 4.71 | 1.58, 20.3 | 0.014 | |
| ppi | 177 | |||
| 0 | — | — | ||
| 1 | 1.41 | 0.57, 4.01 | 0.488 | |
| steroids | 177 | |||
| 0 | — | — | ||
| 1 | 0.71 | 0.31, 1.75 | 0.431 | |
| smoking | 177 | |||
| 0 | — | — | ||
| 1 | 1.26 | 0.60, 2.73 | 0.548 | |
| statins | 177 | 1.96 | 0.63, 8.66 | 0.299 |
| Bevacizumab | 177 | |||
| 0 | — | — | ||
| 1 | 3.97 | 0.90, 17.6 | 0.060 | |
| Cisplatin | 177 | |||
| 0 | — | — | ||
| 1 | 0.77 | 0.17, 2.51 | 0.687 | |
| Carboplatin | 177 | |||
| 0 | — | — | ||
| 1 | 1.43 | 0.65, 3.06 | 0.358 | |
| Pemetrexed | 177 | |||
| 0 | — | — | ||
| 1 | 1.09 | 0.34, 2.99 | 0.878 | |
| Gemcitabine | 177 | |||
| 0 | — | — | ||
| 1 | 2.39 | 0.83, 6.46 | 0.091 | |
| Cetuximab | 177 | |||
| 0 | — | — | ||
| 1 | 0.00 | 0.989 | ||
| Trastuzumab | 177 | |||
| 0 | — | — | ||
| 1 | 0.00 | 0.989 | ||
| VEGF_TKI | 177 | |||
| 0 | — | — | ||
| 1 | 0.71 | 0.16, 2.30 | 0.602 | |
| eGFR_CRE_5year_decrease_10 | 177 | 2.15 | 1.71, 2.81 | <0.001 |
| ICI_Class | 177 | |||
| PD1 | — | — | ||
| Combination | 1.58 | 0.41, 5.18 | 0.467 | |
| CTLA4 | 0.50 | 0.03, 2.88 | 0.517 | |
| PDL1 | 1.44 | 0.55, 3.52 | 0.437 | |
| pre_CRE_180days | 177 | 2.88 | 1.15, 7.39 | 0.024 |
| 1 OR = Odds Ratio, CI = Confidence Interval | ||||
Fine & Grey model for all
## 11 cases omitted due to missing values| Characteristic | N | HR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| year_10 | 2,653 | 1.33 | 1.16, 1.52 | <0.001 |
| male | 2,653 | |||
| 0 | — | — | ||
| 1 | 0.72 | 0.55, 0.95 | 0.019 | |
| Race | 2,653 | |||
| Asian | — | — | ||
| Black | 2.57 | 0.73, 9.05 | 0.140 | |
| Other/Unknown | 1.94 | 0.52, 7.26 | 0.320 | |
| White | 2.62 | 0.83, 8.30 | 0.100 | |
| htn | 2,653 | |||
| 0 | — | — | ||
| 1 | 1.15 | 0.71, 1.85 | 0.570 | |
| cad | 2,653 | |||
| 0 | — | — | ||
| 1 | 1.62 | 1.23, 2.13 | <0.001 | |
| ace_arb | 2,653 | |||
| 0 | — | — | ||
| 1 | 1.26 | 0.89, 1.78 | 0.200 | |
| diu | 2,653 | |||
| 0 | — | — | ||
| 1 | 1.88 | 1.31, 2.70 | <0.001 | |
| ppi | 2,653 | |||
| 0 | — | — | ||
| 1 | 1.04 | 0.72, 1.49 | 0.840 | |
| steroids | 2,653 | |||
| 0 | — | — | ||
| 1 | 0.81 | 0.57, 1.15 | 0.240 | |
| smoking | 2,653 | |||
| 0 | — | — | ||
| 1 | 1.05 | 0.79, 1.40 | 0.720 | |
| statins | 2,653 | 1.89 | 1.22, 2.94 | 0.005 |
| Bevacizumab | 2,653 | |||
| 0 | — | — | ||
| 1 | 0.85 | 0.47, 1.52 | 0.580 | |
| Cisplatin | 2,653 | |||
| 0 | — | — | ||
| 1 | 0.71 | 0.45, 1.14 | 0.160 | |
| Carboplatin | 2,653 | |||
| 0 | — | — | ||
| 1 | 1.01 | 0.75, 1.35 | 0.960 | |
| Pemetrexed | 2,653 | |||
| 0 | — | — | ||
| 1 | 1.44 | 1.00, 2.06 | 0.049 | |
| Gemcitabine | 2,653 | |||
| 0 | — | — | ||
| 1 | 0.96 | 0.63, 1.47 | 0.850 | |
| Cetuximab | 2,653 | |||
| 0 | — | — | ||
| 1 | 0.17 | 0.02, 1.25 | 0.082 | |
| Trastuzumab | 2,653 | |||
| 0 | — | — | ||
| 1 | 0.61 | 0.19, 1.93 | 0.400 | |
| VEGF_TKI | 2,653 | |||
| 0 | — | — | ||
| 1 | 1.51 | 1.03, 2.21 | 0.036 | |
| eGFR_CRE_baseline | 2,653 | 0.98 | 0.98, 0.99 | <0.001 |
| ICI_Class | 2,642 | |||
| PD1 | — | — | ||
| Combination | 1.35 | 0.91, 2.00 | 0.130 | |
| CTLA4 | 0.68 | 0.32, 1.42 | 0.300 | |
| PDL1 | 0.93 | 0.63, 1.35 | 0.690 | |
| cancer_type | 2,653 | |||
| breast | — | — | ||
| cutaneous / melanoma | 1.41 | 0.49, 4.06 | 0.520 | |
| gi | 1.92 | 0.67, 5.57 | 0.230 | |
| gu | 2.34 | 0.83, 6.60 | 0.110 | |
| gyn | 2.06 | 0.64, 6.65 | 0.230 | |
| head and neck | 0.78 | 0.23, 2.72 | 0.700 | |
| heme | 1.73 | 0.54, 5.56 | 0.360 | |
| neuro | 0.39 | 0.04, 3.63 | 0.410 | |
| sarcoma | 0.00 | 0.00, 0.00 | <0.001 | |
| thoracic | 1.83 | 0.65, 5.13 | 0.250 | |
| pre_CRE_180days | 2,653 | 2.06 | 1.63, 2.59 | <0.001 |
| 1 HR = Hazard Ratio, CI = Confidence Interval | ||||